LittleDabbie
- Posts
- 11,813
- Reactions
- 20,319
- Joined
- Mar 9, 2014
- Points
- 438
Surrey, BC / ACCESSWIRE / November 6, 2014 / (OTCPK: VRCI) Verde Science, Inc., a Medical Research and Development Company focused on effective treatments for emerging and contemporary health issues, is pleased to announce that it has executed a definitive pharmaceutical development agreement with Sterkem Group (www.sterkempharma.com) a Mumbai, India based pharmaceutical firm. The two companies have been collaborating on the design of Verde Science's research and development plan and protocols and have agreed on principles of a long-term association.
Under the terms of the agreement, Sterkem Group will help refine the cannabis-based extracts identified by Verde Science's research and development efforts as effective for the treatment of specific medical conditions, into deliverable and marketable pharmaceutical formulations. The companies will share revenues from the sale of products and licensing fees.
Harp Sangha, Verde's CEO, explained "I am pleased to formally add Sterkem Group to our research group. The Sterkem team is well known to us, since we have been working closely for a long time. The principals and researchers of Sterkem possess an array of experience and skills that compliment Verde's staff, and enable us to rapidly move forward on our R&D efforts without the time and expense of building our own back end team."
About Verde Science, Inc. (VRCI)
Verde Science, Inc. (www.VerdeScienceInc.com) is a public company trading under the symbol OTCPK: VRCI. The Company is focused on Medical Research and Development, which includes medical marijuana research and the development of effective treatments for emerging and contemporary health issues.
http://www.baystreet.ca/viewarticle.aspx?id=422568
Under the terms of the agreement, Sterkem Group will help refine the cannabis-based extracts identified by Verde Science's research and development efforts as effective for the treatment of specific medical conditions, into deliverable and marketable pharmaceutical formulations. The companies will share revenues from the sale of products and licensing fees.
Harp Sangha, Verde's CEO, explained "I am pleased to formally add Sterkem Group to our research group. The Sterkem team is well known to us, since we have been working closely for a long time. The principals and researchers of Sterkem possess an array of experience and skills that compliment Verde's staff, and enable us to rapidly move forward on our R&D efforts without the time and expense of building our own back end team."
About Verde Science, Inc. (VRCI)
Verde Science, Inc. (www.VerdeScienceInc.com) is a public company trading under the symbol OTCPK: VRCI. The Company is focused on Medical Research and Development, which includes medical marijuana research and the development of effective treatments for emerging and contemporary health issues.
http://www.baystreet.ca/viewarticle.aspx?id=422568